血清角质素在肺癌诊断及鉴别诊断中的应用

CLINICAL APPLICATION OF SERUM CYFRA21-1 ASSAY IN THE DIAGUOSIS OF LUNG CANCER

目的 研究CYFRA2 1 - 1在肺癌诊断、鉴别诊断中的临床应用价值。方法 应用酶联免疫法 (EIA)测定 1 1 0例健康人 ,92例非肿瘤肺疾病和 42 3例癌症患者 (其中包括 1 2 3例肺癌、97例肝癌、1 0 5例乳腺癌和 1 0 8例鼻咽癌 )血清中的CYFRA2 1 - 1的水平。结果 肺癌组CYFRA2 1 - 1的水平为 (8.2 4± 6 .72 ) μg/L明显高于健康对照组 (1 .67± 0 .68) μg/L及良性肺疾病组 (1 .92± 0 .95) μg/L ,差异均有高度显著性 (P <0 .0 0 1 )。以 >3 .3μg/L为阳性判断值 ,各组别阳性率分别为 :良性肺疾病组 5 .4 %、肺癌组 61 .0 %、乳腺癌组 2 6 .7%、肝癌组 2 3 .7%、鼻咽癌组 1 2 .0 %。经统计学分析 ,肺癌组其含量及阳性率与其他组别之间差异有显著性 (P <0 .0 5)。不同组织类型肺癌阳性率在 35 .7%～ 76 .1 %,其中以鳞癌为最高。结论 血清中CYFRA2 1 - 1的测定对肺癌的实验室诊断 ,尤其是鳞癌的诊断有重要的临床应用价值 ,它是敏感、特异性较高的肺癌肿瘤标志物。

Objective To study the significance of serum CYFRA21-1 in diagnosis of lung cancer. Methods The serum CYFRA21-1 levels among 110 healthy persons, 92 patients of lung disease without tumor and 423 patients with various cancer (including lung cancer, et al) were measured by Enzyme-linked immunosortbent assay. Results Average level of CYFRE21-1 in the group of lung cancer was (8.24±6.27)μg/L, which was significantly higher than that of normal controls (1.67±0.68) μg/L and that of patients with various benign diseases (P<0.001). The positive rate in lung cancer group is 61.0 but only 5.4% in ono-carcinoma group, which was significantly higher than those groups (P<0.05). For Lung cancer, the diagnosis sensitivity of CYFRA21-1 is 61.0, specificity is 97.6 and diagnosis accuracy is 83.6%. The positive rates for squamous cell carcinoma adeno-carcinoma and small cell carcinoma were 76.1%, 47.6% and 35.7%. Conclusion It is suggested detection of serum CYFRA21-1 level is a useful tumor marker for the diagnosis of lung cancer.